Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial ( COMING study)
Authors' conclusion
This prospective trial showed that semaglutide has more pronounced glucose- and body mass index-lowering effects and reduces liver fat percentage and visceral fat area and that dulaglutide has less gastrointestinal symptoms and superior Diabetes Treatment-Related Quality of Life scores related to pain and gastrointestinal symptoms.
Study context
- Population
- Japanese patients with T2D and HbA1c ≥7%107 completed
- Participants
- 120 patients
- Comparison
- Once-weekly dulaglutide vs semaglutide
- Dulaglutiden = 59
- Semaglutiden = 61
- Primary endpoint
- Difference of HbA1c level between the two groups
- Follow-up
- 24 weeks
Methodological detailsparallel-group, multicentre, open-label
- Parallel-group
- Multicentre
- Open-label
Primary result
As reported in the abstract
HbA1c (baseline–24 weeks)
- Semaglutide: HbA1c 7.9 ± 0.5% to 6.7 ± 0.5%
- Dulaglutide: HbA1c 8.1 ± 0.6% to 7.4 ± 0.8%
- Semaglutide vs Dulaglutide: P < 0.0001
Further findings
| Outcome | P value |
|---|---|
| Reduction in BMI and visceral fat areaGreater reduction with semaglutide | P < 0.05, respectively |
| Achievement of HbA1c <7%Higher with semaglutide | P < 0.0001 |
LDL-C, ALT, γ-GTP, apolipoprotein B/A1 ratio, liver to spleen ratio (CT)
- LDL-C, ALT and γ-GTP decreased in semaglutide group
- Only semaglutide significantly improved apolipoprotein B/A1 ratio
- Liver to spleen ratio on CT significantly elevated only with semaglutide
Diabetes Treatment-Related Quality of Life scores (pain, gastrointestinal symptoms)
- Superior in the dulaglutide group
Safety
Gastrointestinal symptoms
P < 0.01
Original publication
Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial ( COMING study). Diabetes Obes Metab. Published 30 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →